BLOG
Is there an age limit for launching your first startup? Is 50 “too old” to become a founder ?
Judging by photos of startup events packed with 30-something entrepreneurs—often women—you might think so.
The success factors behind the success story of Mablink, a French ADC company to be acquired by Lilly
The disclosed factors and the non-disclosed price explained by a previous SAB member
Carl Vogt et Eric Bauce : choix controversé de recteurs
En 1874, Carl Vogt devint le premier Recteur de la nouvelle Université de Genève. En 2023, Eric Bauce, choisi par l’Assemblée de l’Université, en deviendra peut-être le nouveau Recteur. Il est frappant de voir le télescopage des controverses avec deux personnalité.
Carl Vogt : un anthropologue de son siècle, comme Charles Darwin
La récente décision de débaptiser un bâtiment Uni Carl Vogt à Genève donne l’occasion de redécouvrir les diverses facettes de l’œuvre de Carl Vogt au-delà de son héritage raciste et misogyne.
La résilience de la démocratie américaine grâce aux élections des Secrétaires d’Etat
Brad Raffensperger, Secrétaire d’Etat de Géorgie devint connu internationalement lorsqu’il refusa de « trouver » 11’780 votes lors d’un appel avec le Président Trump.
Ce sujet d’élection américaine est à l’évidence en dehors des sciences de la vie mais les lecteurs verront à la fin le lien avec Genève et un engagement plus personnel de votre serviteur.
NEWS
NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1
Interim Data from ImmunoNET trial demonstrate NP137 potential to overcome secondary resistance to Immune Checkpoint Inhibitors
TheraPPI completes a first closing of Pre-Seed Financing to advance its lead oncology program targeting a novel protein interaction
TheraPPI scientists publish preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
NETRIS Pharma Welcomes Eric Falcand as Independent Director to Its Board of Directors
NETRIS Pharma announces the appointment of Eric Falcand to its Board of Directors as Independent Director
NETRIS Pharma Announces FDA Orphan Drug Designation (ODD) for NP137 in Pancreatic Cancer Treatment
NETRIS Pharma announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NP137 for the treatment of pancreatic cancer
NETRIS Pharma appoints Ségolène BISOT-LOCARD as Chief Medical Officer
NETRIS Pharma announces the appointment Ségolène BISOT-LOCARD, MD, as Chief Medical Officer (CMO)
TheraPPI Announces Publication of Preclinical Data in Nature Communications, Demonstrating the Inhibition of ERK/MyD88 Interaction as a Promising Cancer Treatment
TheraPPI scientists publish preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
NETRIS Pharma is awarded €3.9m to Lead the Development of a Novel Therapy in Endometriosis
NETRIS Pharma announces the launch of a new program in endometriosis founded by BPI under the “Innovation in Biotherapies and Bioproduction” scheme within France 2030
TheraPPI Bioscience Awarded the French Tech Emergence Grant
TheraPPI has been awarded the French Tech Emergence Grant by BPI France in the context of the “Programme France 2030”
TheraPPI Bioscience Awarded Reputable French Tech Seed Label
The Pouss@LYS consortium has recently given a favorable recommendation on French Tech Seed label to TheraPPI
NETRIS Pharma extends Series A to €24.4 million and reinforces its leadership team and Board of Directors
NETRIS Pharma has expanded its ongoing Series A reaching €24.4 million with the closing of a €7.5 million extension
TheraPPI Bioscience awarded a Fongit Innovation Fund (FIF) seed loan
The Fondation Genevoise pour l’Innovation Technologique has granted a FIF seed loan of CHF100 000 to TheraPPI
TheraPPI Bioscience announces an exclusive license agreement with PULSALYS to develop novel drugs in oncology and rare diseases
PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction